David Klenerman, a distinguished Professor of Biophysical Chemistry at the University of Cambridge and a key figure at the UK Dementia Research Institute, alongside his long-time collaborator Shankar Balasubramanian, has been instrumental in ushering in a new era of genomics through their pioneering work on sequencing by synthesis. Their invention, which drastically reduced the cost and time required for DNA sequencing, led to the formation of Solexa, a company later acquired by Illumina Inc., and fundamentally transformed biological research and medicine. The duo recently shared insights into the journey of their groundbreaking technology and the critical factors for biotech startup success at a panel discussion hosted by the Millennium Technology Prize in Helsinki, Finland, an event that underscored the profound impact of their contributions.
The Genesis of a Genomic Revolution
The conceptual leap that would eventually define next-generation sequencing began to take shape in the mid-1990s, following Klenerman and Balasubramanian’s arrival at the University of Cambridge in 1994-95. At the time, the field of physical chemistry was abuzz with advancements in single-molecule visualization, a technique that allowed scientists to observe individual molecules in motion and witness biological processes unfold in real-time. This capability sparked an idea: to directly observe the enzyme DNA polymerase as it incorporated nucleotides into a DNA strand.
Their initial research, supported by a successful grant from the Biotechnology and Biological Sciences Research Council (BBSRC), aimed to attach a DNA template primer to a bead and then introduce fluorescently labeled nucleotides. The intention was to use fluorescence-based imaging to track the polymerase’s activity. However, during the course of these experiments, Klenerman and Balasubramanian recognized a transformative potential in their setup. By color-coding the individual nucleotides, they realized the same experimental design could be repurposed to not just observe, but to actually copy and decode DNA sequences.
This realization was immediately followed by a crucial calculation: if this experimental setup could be scaled to run millions of DNA sequences simultaneously on a surface, the technology could achieve a million-fold acceleration compared to the prevailing sequencing methods. This was a radical proposition at a time when Sanger sequencing, while robust, was slow and prohibitively expensive for large-scale applications.
The conceptual breakthrough was underpinned by an emerging chemical innovation of the 1990s: reversible terminator nucleotides. These specially engineered nucleotides featured a removable blocking group at their 3’-OH position, which allowed for precise, stepwise control over DNA synthesis. The polymerase would add only one nucleotide at a time, with the blocking group preventing further incorporation. After imaging the incorporated fluorophore, the blocking group could be chemically cleaved, preparing the strand for the addition of the next nucleotide. This elegant chemistry, combined with a massively parallel execution, meant that sequencing even short stretches of around 30 bases could, through computational reconstruction, provide insights into entire human genomes.
A Pivotal Era: The Human Genome Project and the Demand for Individual Genomics
The timing of this innovation was serendipitous. The year 2000 marked a monumental achievement in scientific history with the announcement by President Bill Clinton that the consensus human genome had been sequenced. This landmark project, however, had cost approximately $2.7 billion and taken over a decade to complete, highlighting the immense challenges and costs associated with sequencing. While a triumph, the consensus genome represented an average, not the unique genetic blueprint of an individual. The scientific community immediately shifted its focus to the next grand challenge: developing a cost-effective and rapid method to sequence individual human genomes.
Klenerman and Balasubramanian’s nascent technology, with its potential for unprecedented speed and scalability, was perfectly positioned to address this critical need. They found themselves in the "right place at the right time," holding the key to unlocking personalized genomics. The shift from a single, expensive reference genome to the routine sequencing of individual genomes promised to revolutionize medicine, drug discovery, and our fundamental understanding of human biology.
From Academic Insight to Commercial Imperative: The Solexa Journey
The journey from a groundbreaking scientific idea to a commercially viable product required a profound shift in mindset. Klenerman credits a pivotal conversation with Alan Munro, then master at Christ’s College, Cambridge, who had prior experience in university spin-outs, as the catalyst for this commercialization drive. Munro emphasized three crucial points: first, that a technology’s true impact is realized only through widespread adoption; second, that academic research grants could not provide the exponentially increasing capital required for development; and third, that a spin-out company was the only viable vehicle to secure such substantial funding.
Acting on Munro’s advice, Klenerman and Balasubramanian approached Abingworth, a life-science investment company based in London. Their initial pitch was unconventional. Unlike typical startups presenting extensive preliminary data for incremental improvements, they arrived with limited proof-of-concept data from their postdocs but proposed a technology promising a million-fold improvement. This bold claim, despite the scarcity of empirical evidence, intrigued Abingworth. Following a rigorous due diligence process, Abingworth decided to invest a modest sum, enabling the establishment of Solexa and further feasibility research. This initial capital was crucial, not just for funding, but also for the strategic guidance Abingworth provided in shaping the company’s direction.
The decision to form a spin-out company proved prescient. While the idea originated in the mid-1990s, it took approximately a decade for Solexa to develop a machine capable of sequencing a genome, starting with viral genomes and eventually the human genome. Klenerman reflects on this timeline with a sense of accomplishment, noting that transforming a concept from paper to a marketable machine in ten years is remarkably swift in practical terms, underscoring the efficiency and focus afforded by a commercial enterprise compared to academic research.
Initially, the commercial aspect was a secondary consideration, driven primarily by the desire to see their transformative scientific idea reach its full potential. The market need for individual genome sequencing was undeniable, and Solexa became the necessary vehicle to achieve that impact.
The Illumina Acquisition: Scaling for Global Impact
By 2007, Solexa had developed an instrument capable of sequencing an individual human genome, but to truly fulfill its potential and achieve widespread adoption, it required significant further investment in development, manufacturing, and a global sales force. At this juncture, Illumina, a prominent player in DNA arrays, entered the picture. Illumina sought to integrate a robust sequencing technology into its portfolio, and Solexa needed the infrastructure to scale. The acquisition of Solexa by Illumina in 2007 was a strategic alignment that brought together Solexa’s innovative sequencing technology with Illumina’s extensive sales network and manufacturing capabilities.
Klenerman notes that the founders were not heavily involved in the intricacies of the acquisition, which proceeded smoothly due to strong alignment between the two companies’ objectives. While the legal work was substantial, the strategic fit was clear. Post-acquisition, Illumina invested heavily, improving the technology’s performance by several orders of magnitude, making it the dominant platform for next-generation sequencing globally.
One notable consequence, however, was that the company’s operations did not remain in the UK. This reflected the reality of the sequencing landscape at the time: there was no European or UK alternative prepared to provide the colossal investment required to scale the technology independently. Building out the necessary sales force and manufacturing capabilities from scratch would have demanded prohibitive sums, making the acquisition by a larger, established entity like Illumina a logical, albeit geographically shifting, progression. Industry analysts widely regard the Solexa acquisition as one of the most impactful in biotech history, fundamentally reshaping the life sciences industry and solidifying Illumina’s position as a genomics powerhouse.
Navigating the UK Biotech Landscape: Challenges in Commercialization
Klenerman highlights a persistent challenge within the UK biotech ecosystem: the difficulty in retaining successful companies that scale to a significant size. Often, promising UK ventures reach a certain stage of development only to be acquired by larger American companies, which typically possess greater resources and a higher appetite for risk. This dynamic prevents the formation of a "virtuous circle" where successful UK-based companies generate wealth and expertise that can then be reinvested locally, nurturing a new generation of domestic startups and fostering sustained economic growth.
The global next-generation sequencing market was valued at over $10 billion in 2022 and is projected to grow substantially, underscoring the immense economic potential that the UK could capture if it were better equipped to scale and retain such enterprises. While the UK consistently ranks high in scientific output and boasts world-class research institutions like the University of Cambridge, translating this innovation into large-scale, domestically headquartered commercial success remains an ongoing struggle.
Klenerman points to examples like Finland, which has developed effective structures to enable companies to scale while remaining within the country. He suggests that the UK might explore similar strategies, such as government investment via "golden share" models or encouraging greater investment from UK banks, to secure these high-impact companies within national borders and ensure they contribute more directly to the UK’s GDP. This strategic shift is crucial for transforming the UK from a hub of scientific discovery into a global leader in biotech commercialization.
Guidance for Aspiring Academic Entrepreneurs
For academics contemplating the commercialization of their research, Klenerman offers clear, actionable advice. The foremost recommendation is to seek out and engage with individuals who have successfully established spin-out companies in their local area. These conversations can provide invaluable insights into the intricacies of the process, including potential deal structures, key developmental milestones, and the practical realities of founding a business, all from someone with firsthand experience.
Concurrently, academics should actively engage with their university’s technology transfer office, which can provide institutional support, navigate intellectual property rights, and connect researchers with relevant resources. These combined efforts will equip aspiring entrepreneurs with a more comprehensive understanding of the landscape, enabling them to make informed and balanced decisions.
Klenerman also emphasizes the rarity and preciousness of such opportunities. He urges academics to recognize when they have a potentially transformative idea and to seize the moment. The risk of failure, he argues, should not be a deterrent. Instead, it should be viewed as a learning experience. Even if a venture does not succeed, the knowledge gained about business formation and the commercialization process is invaluable for future endeavors. His own journey with Solexa began without certainty of its ultimate success, but with a conviction that the idea was profoundly worth exploring.
Current Research Frontiers: Tackling Neurodegenerative Diseases
Having profoundly impacted genomics, David Klenerman’s current research focus has shifted to another critical area of human health: neurodegenerative diseases. He is now applying the very technology that underpins sequencing by synthesis – the imaging of single molecules – to investigate protein aggregates associated with debilitating conditions such as Alzheimer’s and Parkinson’s, specifically focusing on alpha-beta tau and alpha-synuclein.
His lab is pursuing two main avenues of research. First, they are working on detecting small, nanoscopic aggregates of these proteins, which are precursors to the larger inclusions characteristic of these diseases in the brain. By developing methods to detect these aggregates in blood samples, Klenerman’s team believes they can identify potential biomarkers for the early diagnosis of these conditions, with promising data already supporting this hypothesis. Early diagnosis is crucial for intervention and management of these progressive diseases.
Second, his team is delving into the fundamental mechanisms that drive increased protein aggregation. By understanding these processes at a molecular level, they aim to rationally design novel therapeutic strategies to intervene and potentially treat neurodegenerative diseases. This work holds immense promise for millions worldwide affected by these conditions, demonstrating Klenerman’s continued commitment to leveraging advanced biophysical chemistry for medical breakthroughs.
The Enduring Impact of the Millennium Technology Prize
The recognition bestowed by the Millennium Technology Prize was significant for Klenerman, personally raising his profile within the global scientific community. More importantly, he views the prize as a testament to the entire team behind Solexa. It provided international recognition for the Cambridge-based group that developed the sequencing by synthesis technology, allowing them to take immense pride in their collective achievement. Such accolades not only celebrate individual brilliance but also underscore the collaborative nature of scientific innovation and its profound societal impact, validating the long and often arduous journey from a lab idea to a world-changing technology. The legacy of David Klenerman and Shankar Balasubramanian continues to unfold, shaping the future of medicine and scientific discovery.
